Search research articles
Contact Us
Filters
Showing results (91-100 of 108) with videos related to
Page
of 11
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 4, 2019
Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 × 2, Phase II Trial
Michael Lübbert, Olga Grishina, Claudia Schmoor, et al.
Journal of Cancer Research and Clinical Oncology
|
September 28, 2022
Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry
Maher Hanoun, Leo Ruhnke, Michael Kramer, et al.
British Journal of Cancer
|
August 4, 2023
Impact of BMI on patient outcome in acute myeloid leukaemia patients receiving intensive induction therapy: a real-world registry experience
Julius C Enßle, Sebastian Wolf, Sebastian Scheich, et al.
Haematologica
|
February 23, 2023
Impact of trisomy 19 on outcome according to genetic makeup in patients with acute myeloid leukemia
Sabine Kayser, David Martínez-Cuadrón, Rebeca Rodriguez-Veiga, et al.
European Journal of Haematology
|
October 14, 2024
Impact of TP53 Mutation Status in Elderly AML Patients When Adding All-Trans Retinoic Acid or Valproic Acid to Decitabine
Helena Bresser, Claudia Schmoor, Olga Grishina, et al.
The Journal of Clinical Investigation
|
May 9, 2023
Patient-tailored adoptive immunotherapy with EBV-specific T cells from related and unrelated donors
Agnes Bonifacius, Britta Lamottke, Sabine Tischer-Zimmermann, et al.
The Lancet. Haematology
|
April 7, 2024
Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial
Matthias Stelljes, Jan Moritz Middeke, Gesine Bug, et al.
Blood
|
July 30, 2025
Disease risk but not remission status determines transplant outcomes in AML: long-term outcomes of the ASAP trial
Matthias Stelljes, Jan Moritz Middeke, Gesine Bug, et al.
Haematologica
|
April 24, 2024
Time from diagnosis to treatment has no impact on survival in newly diagnosed acute myeloid leukemia treated with venetoclax-based regimens
David Baden, Sven Zukunft, Gema Hernandez, et al.
Blood
|
June 5, 2020
Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?
Christoph Röllig, Michael Kramer, Christoph Schliemann, et al.
Page
of 11
Search research articles
Search
Showing results (91-100 of 108) with videos related to
Sort By:
Page
of 11
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 4, 2019
Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 × 2, Phase II Trial
Michael Lübbert, Olga Grishina, Claudia Schmoor, et al.
Journal of Cancer Research and Clinical Oncology
|
September 28, 2022
Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry
Maher Hanoun, Leo Ruhnke, Michael Kramer, et al.
British Journal of Cancer
|
August 4, 2023
Impact of BMI on patient outcome in acute myeloid leukaemia patients receiving intensive induction therapy: a real-world registry experience
Julius C Enßle, Sebastian Wolf, Sebastian Scheich, et al.
Haematologica
|
February 23, 2023
Impact of trisomy 19 on outcome according to genetic makeup in patients with acute myeloid leukemia
Sabine Kayser, David Martínez-Cuadrón, Rebeca Rodriguez-Veiga, et al.
European Journal of Haematology
|
October 14, 2024
Impact of TP53 Mutation Status in Elderly AML Patients When Adding All-Trans Retinoic Acid or Valproic Acid to Decitabine
Helena Bresser, Claudia Schmoor, Olga Grishina, et al.
The Journal of Clinical Investigation
|
May 9, 2023
Patient-tailored adoptive immunotherapy with EBV-specific T cells from related and unrelated donors
Agnes Bonifacius, Britta Lamottke, Sabine Tischer-Zimmermann, et al.
The Lancet. Haematology
|
April 7, 2024
Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial
Matthias Stelljes, Jan Moritz Middeke, Gesine Bug, et al.
Blood
|
July 30, 2025
Disease risk but not remission status determines transplant outcomes in AML: long-term outcomes of the ASAP trial
Matthias Stelljes, Jan Moritz Middeke, Gesine Bug, et al.
Haematologica
|
April 24, 2024
Time from diagnosis to treatment has no impact on survival in newly diagnosed acute myeloid leukemia treated with venetoclax-based regimens
David Baden, Sven Zukunft, Gema Hernandez, et al.
Blood
|
June 5, 2020
Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?
Christoph Röllig, Michael Kramer, Christoph Schliemann, et al.
Page
of 11